Lilly Merida Biosciences Acquisition: Eli Lilly to Pay $2.875 Billion for Precision Autoantibody Therapies
Eli Lilly will pay up to $2.875 billion to acquire Merida Biosciences, gaining a precision antibody-degradation platform led by Phase 1 candidate MER511 for Graves’ disease and thyroid eye disease.
Roche Vabysmo PCV Study Shows Sustained Two-Year Results in Difficult-to-Treat nAMD Subtype
New two-year data from Roche’s Phase IIIb/IV SALWEEN trial show that Vabysmo (faricimab) delivers durable vision gains and disease control in Asian patients with polypoidal choroidal vasculopathy (PCV), a severe subtype of neovascular age-related macular degeneration, while cutting treatment visits for the majority of patients.
TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results
Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful results across both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with benefits sustained through week 52.
Abbott Libre Duo 10 Day Wins FDA Authorization as World’s First Dual Glucose-Ketone Sensor
Abbott Libre Duo 10 Day has received FDA authorization as the world’s first dual glucose-ketone biowearable, designed to alert people with diabetes to rising DKA risk while tracking glucose in real time.
Johnson & Johnson’s IMAAVY Nipocalimab-aahu Wins FDA Approval as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia
Johnson & Johnson’s IMAAVY nipocalimab-aahu has received FDA approval as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), based on durable hemoglobin response data from the Phase 2/3 ENERGY study.
IQVIA Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
IQVIA’s AI-enabled Clinical Decision Support Tool, built with Breakthrough T1D, won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year after cutting T1D misdiagnosis screening workload by 99.5% and lifting diagnostic yield 127-fold.
Moderna With MSD Announces Intismeran KEYTRUDA Melanoma Trial Hits Phase 3 Endpoints
Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its RFS and DMFS endpoints in resected stage IIB-IV melanoma, the first positive Phase 3 result for an individualized neoantigen therapy.
Genentech Hillsboro Manufacturing Expansion: Roche Subsidiary to Invest $750 Million in New Oregon Device-Fill Facility
Genentech, Roche’s US subsidiary, will invest approximately $750 million to build a new device fill-finish facility at its Hillsboro, Oregon campus, adding 250 manufacturing jobs and doubling the site’s size ahead of a 2031 commercial start.
BioMarin Alesta Therapeutics Acquisition: BioMarin Acquires Alesta to Secure Oral HPP Candidate ALE1 for $275M Upfront
The BioMarin Alesta Therapeutics acquisition secures lead oral asset ALE1 for $275M upfront plus milestones, expanding BioMarin’s rare disease skeletal pipeline.
AstraZeneca Discontinues Volrustomig Phase III Trial in First-Line Metastatic Non-Small Cell Lung Cancer
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.